143 related articles for article (PubMed ID: 2126347)
1. Behavioural, biochemical and electrophysiological studies on the motor depressant and stimulant effects of bromocriptine.
Jackson DM; Martin LP; Larsson LG; Cox RF; Waszczak BL; Ross SB
Naunyn Schmiedebergs Arch Pharmacol; 1990 Sep; 342(3):290-9. PubMed ID: 2126347
[TBL] [Abstract][Full Text] [Related]
2. Time course of bromocriptine induced excitation in the rat: behavioural and biochemical studies.
Jackson DM; Mohell N; Georgiev J; Bengtsson A; Larsson LG; Magnusson O; Ross SB
Naunyn Schmiedebergs Arch Pharmacol; 1995 Feb; 351(2):146-55. PubMed ID: 7539523
[TBL] [Abstract][Full Text] [Related]
3. Evidence for selective and long-lasting stimulation of "regulatory" dopamine-receptors by bromocriptine (CB 154).
di Chiara G; Porceddu ML; Vargiu L; Stefanini E; Gessa GL
Naunyn Schmiedebergs Arch Pharmacol; 1977 Nov; 300(3):239-45. PubMed ID: 600311
[TBL] [Abstract][Full Text] [Related]
4. Chronic L-DOPA-pretreatment of rats: an electrophysiological and biochemical study in the basal ganglia.
Jackson DM; Walters JR; Miller LP
Brain Res; 1982 Nov; 250(2):271-82. PubMed ID: 6129029
[TBL] [Abstract][Full Text] [Related]
5. Dopamine D-2 receptor agonist-induced behavioural depression: critical dependence upon postsynaptic dopamine D-1 function. A behavioural and biochemical study.
Jackson DM; Ross SB; Larsson LG
Naunyn Schmiedebergs Arch Pharmacol; 1989 Oct; 340(4):355-65. PubMed ID: 2573842
[TBL] [Abstract][Full Text] [Related]
6. Bromocriptine potentiates the behavioural effects of directly and indirectly acting dopamine receptor agonists in mice.
Jenkins OF; Jackson DM
Naunyn Schmiedebergs Arch Pharmacol; 1985 Oct; 331(1):7-11. PubMed ID: 3877878
[TBL] [Abstract][Full Text] [Related]
7. Effects of zonisamide on dopaminergic system.
Okada M; Kaneko S; Hirano T; Mizuno K; Kondo T; Otani K; Fukushima Y
Epilepsy Res; 1995 Nov; 22(3):193-205. PubMed ID: 8991786
[TBL] [Abstract][Full Text] [Related]
8. Synthesis and release of dopamine in rat brain: comparison between substantia nigra pars compacts, pars reticulata, and striatum.
Nissbrandt H; Sundström E; Jonsson G; Hjorth S; Carlsson A
J Neurochem; 1989 Apr; 52(4):1170-82. PubMed ID: 2564423
[TBL] [Abstract][Full Text] [Related]
9. The effectiveness of yohimbine in blocking rat central dopamine autoreceptors in vivo.
van Oene JC; de Vries JB; Horn AS
Naunyn Schmiedebergs Arch Pharmacol; 1984 Oct; 327(4):304-11. PubMed ID: 6514014
[TBL] [Abstract][Full Text] [Related]
10. RDS-127 (2-di-n-propylamino-4,7-dimethoxyindane): central effects of a new dopamine receptor agonist.
Arnerić SP; Long JP; Williams M; Goodale DB; Mott J; Lakoski JM; Gebhart GF
J Pharmacol Exp Ther; 1983 Jan; 224(1):161-70. PubMed ID: 6401334
[TBL] [Abstract][Full Text] [Related]
11. Autoreceptors mediate the inhibition of dopamine synthesis by bromocriptine and lisuride in rats.
Tissari AH; Rossetti ZL; Meloni M; Frau MI; Gessa GL
Eur J Pharmacol; 1983 Aug; 91(4):463-8. PubMed ID: 6413231
[TBL] [Abstract][Full Text] [Related]
12. Turnover of dopamine and dopamine metabolites in rat brain: comparison between striatum and substantia nigra.
Nissbrandt H; Carlsson A
J Neurochem; 1987 Sep; 49(3):959-67. PubMed ID: 3612134
[TBL] [Abstract][Full Text] [Related]
13. A comparison of the potencies of various dopamine receptor agonists in models for pre- and postsynaptic receptor activity.
Feenstra MG; Sumners C; Goedemoed JH; de Vries JB; Rollema H; Horn AS
Naunyn Schmiedebergs Arch Pharmacol; 1983 Sep; 324(2):108-15. PubMed ID: 6646238
[TBL] [Abstract][Full Text] [Related]
14. Dopamine receptors: effects of chronic L-dopa and bromocriptine treatment in an animal model of Parkinson's disease.
Schneider MB; Murrin LC; Pfeiffer RF; Deupree JD
Clin Neuropharmacol; 1984; 7(3):247-57. PubMed ID: 6435870
[TBL] [Abstract][Full Text] [Related]
15. Dopamine D2 receptors and dopamine metabolism. Relationship between biochemical and behavioural effects of substituted benzamide drugs.
Magnusson O; Fowler CJ; Köhler C; Ogren SO
Neuropharmacology; 1986 Feb; 25(2):187-97. PubMed ID: 2939362
[TBL] [Abstract][Full Text] [Related]
16. Hypothesis: bromocriptine lacks intrinsic dopamine receptor stimulating properties.
Jackson DM; Jenkins OF
J Neural Transm; 1985; 62(3-4):219-30. PubMed ID: 3897455
[TBL] [Abstract][Full Text] [Related]
17. D1 dopamine receptor stimulation enables the postsynaptic, but not autoreceptor, effects of D2 dopamine agonists in nigrostriatal and mesoaccumbens dopamine systems.
Wachtel SR; Hu XT; Galloway MP; White FJ
Synapse; 1989; 4(4):327-46. PubMed ID: 2532422
[TBL] [Abstract][Full Text] [Related]
18. Long-term decreases in striatal dopamine, 3,4-dihydroxyphenylacetic acid, and homovanillic acid after a single injection of amphetamine in iprindole-treated rats: time course and time-dependent interactions with amfonelic acid.
Steranka LR
Brain Res; 1982 Feb; 234(1):123-36. PubMed ID: 7059818
[TBL] [Abstract][Full Text] [Related]
19. Stimulation of "regulatory" dopamine receptors by bromocriptine (CB-154).
Di Chiara G; Porceddu ML; Vargiu L; Gessa GL
Pharmacology; 1978; 16 Suppl 1():135-42. PubMed ID: 643899
[TBL] [Abstract][Full Text] [Related]
20. Effect of estrogens on dopamine autoreceptors in male rats.
Piccardi P; Bernardi F; Rossetti Z; Corsini G
Eur J Pharmacol; 1983 Jul; 91(1):1-9. PubMed ID: 6617733
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
